Enhanced bioprocess control to advance the manufacture of mesenchymal stromal cell‐derived extracellular vesicles in stirred‐tank bioreactors
Biotechnology and Bioengineering · 2023-09 · 120 (9) · 2725-2741
DOI: 10.1002/bit.28378 ↗At a glance
Journal article in Biotechnology and Bioengineering, published online on 2023-06-08. Written by Marta H G Costa and 10 co-authors. Institution: Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal. Major MEDLINE topics: Extracellular Vesicles, Mesenchymal Stem Cells. Cited 44 times so far (Crossref); 60 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Fundação para a Ciência e a Tecnologia.
Abstract (original language)
Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) act as signaling mediators of cellular responses. However, despite representing a promising alternative to cell‐based therapies, clinical translation of EVs is currently limited by their lack of scalability and standardized bioprocessing. Herein, we integrated scalable downstream processing protocols with standardized expansion of large numbers of viable cells in stirred‐tank bioreactors to improve EV production. Higher EV yields were linked to EV isolation by tangential flow filtration followed by size exclusion chromatography, rendering 5 times higher number of EVs comparatively to density gradient ultracentrifugation protocols. Additionally, when compared to static culture, EV manufacture in bioreactors resulted in 2.2 higher yields. Highlighting the role of operating under optimal cell culture conditions to maximize the number of EVs secreted per cell, MSCs cultured at lower glucose concentration favored EV secretion. While offline measurements of metabolites concentration can be performed, in this work, Raman spectroscopy was also applied to continuously track glucose levels in stirred‐tank bioreactors, contributing to streamline the selection of optimal EV collection timepoints. Importantly, MSC‐derived EVs retained their quality attributes and were able to stimulate angiogenesis in vitro, therefore highlighting their promising therapeutic potential.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.
- iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
- Department of Regenerative Medicine, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
ORCID profiles: Marta H G Costa, Inês A Isidro
Funding
- Fundação para a Ciência e a Tecnologia
Cite
APA
Costa, M. H. G., Costa, M. S., Painho, B., Sousa, C. D., Carrondo, I., Oltra, E., Pelacho, B., Prosper, F., Isidro, I. A., Alves, P., & Serra, M. (2023). Enhanced bioprocess control to advance the manufacture of mesenchymal stromal cell‐derived extracellular vesicles in stirred‐tank bioreactors. Biotechnology and Bioengineering, 120(9), 2725-2741. https://doi.org/10.1002/bit.28378
Vancouver
Costa MHG, Costa MS, Painho B, Sousa CD, Carrondo I, Oltra E, et al. Enhanced bioprocess control to advance the manufacture of mesenchymal stromal cell‐derived extracellular vesicles in stirred‐tank bioreactors. Biotechnology and Bioengineering. 2023;120(9):2725-2741. doi:10.1002/bit.28378
BibTeX
@article{Costa2023,
author = {Costa, Marta H G and Costa, Margarida S and Painho, Beatriz and Sousa, Carolina D and Carrondo, Inês and Oltra, Enrique and Pelacho, Beatriz and Prosper, Felipe and Isidro, Inês A and Alves, Paula and Serra, Margarida},
title = {Enhanced bioprocess control to advance the manufacture of mesenchymal stromal cell‐derived extracellular vesicles in stirred‐tank bioreactors},
journal = {Biotechnology and Bioengineering},
year = {2023},
volume = {120},
number = {9},
pages = {2725--2741},
doi = {10.1002/bit.28378}
}
EUVIMED